Você está na página 1de 7

Original Research ajog.

org

GYNECOLOGY
Combined hormonal contraception use in reproductive-age
women with contraindications to estrogen use
Julianne R. Lauring, MD; Erik B. Lehman, MS; Timothy A. Deimling, MD; Richard S. Legro, MD;
Cynthia H. Chuang, MD, MSc

BACKGROUND: The Centers for Disease Control and Prevention’s US sociodemographic data in women with and without contraindications to
Medical Eligibility Criteria for Contraceptive Use recommends that com- estrogen use.
bined hormonal contraceptives (ie, birth control pills, contraceptive patch, RESULTS: The MyNewOptions baseline study sample included 987 adult
vaginal ring) should be avoided in women with specific medical conditions women who were mostly young (46% were 18e25 years), white (94%),
because of the increased risk of cardiovascular events associated with employed (70%), and married or cohabiting (54%). Thirteen percent (n ¼
estrogen use. Whether women with category 3 (theoretical or proven risk 130) of the sample had a medical contraindication to estrogen-containing
usually outweigh the advantages) or category 4 (unacceptable health risk) contraceptive use: migraine with aura (81%) was the most common
contraindications are appropriately avoiding estrogen-containing com- contraindication, followed by smokers older than age 35 years (7%), hy-
bined hormonal contraceptives is unknown. pertension (11%), history of venous thromboembolism (4%), and diabetes
OBJECTIVE: We describe the prevalence of combined hormonal con- with complications (2%). High use of combined hormonal contraceptives
traceptive use among a sample of reproductive-age women with medical was reported among the women with medical contraindications to estrogen
contraindications to estrogen use. Our hypothesis was that women with at 39% (n ¼ 51). This was not statistically different from women without a
categories 3 and 4 contraindications would use estrogen-containing medical contraindication (47%, P ¼ .1). Among the 130 women with a
contraception less often than women without medical contraindications. contraindication, whether they did or did not use an estrogen-containing
We also explored whether inappropriate estrogen-containing contracep- contraceptive did not vary by education level, income, or weight category.
tive use is related to contraceptive provider characteristics. With respect to their contraceptive prescribers, there were no differences in
STUDY DESIGN: Data are from the baseline survey of the MyNe- prescriber specialty, provider type, or clinic type comparing women using
wOptions study, which included privately insured women residing in and not using an estrogen-containing contraceptive.
Pennsylvania aged 18e40 years, who were sexually active and not CONCLUSION: Among this study sample of reproductive-age women,
intending pregnancy in the next year. Women were surveyed about their there was a high rate of combined hormonal contraceptive use in women
medical conditions, contraceptive use, and characteristics of their con- with a medical contraindication to estrogen use. These women may be at
traceptive provider. Women were considered to have a contraindication to an increased risk for cardiovascular events. Processes need to be
combined hormonal contraceptives if they reported a category 3 or improved to ensure that women with medical contraindications to
category 4 contraindication: hypertension, smokers older than age 35 estrogen-containing contraception are being offered the safest and most
years, a history of venous thromboembolism, diabetes with complications, effective methods, including long-acting reversible contraceptives, such
coronary artery disease, systemic lupus erythematosus with anti- as intrauterine devices and the contraceptive implant.
phospholipid antibodies, breast cancer, or migraine headaches with aura.
c2 tests for general association were used to compare combined hormonal Key words: combined hormonal contraception, medical
contraceptives use, contraceptive health provider characteristics, and contraindications

M ore than 80% of women in the


United States have ever used
hormonal contraception.1 Hormonal
benefits2 and can safely be used by most
women. However, there are certain
medical conditions that increase the
prescribing contraception to women
with medical comorbidities.
In the setting of various health con-
contraception includes estrogen- risk of adverse events associated with ditions, these criteria classify combined
progesterone combined hormonal combined hormonal contraception hormonal contraception use as category
contraception, which can provide use, mostly related to cardiovascular 1 (no restrictions to method use), cate-
effective protection against pregnancy complications. The prevalence of gory 2 (advantages of method generally
with many noncontraceptive health reproductive-age women with medical outweigh the theoretical or proven
contraindications to combined hor- risks), category 3 (theoretical or proven
monal contraception has been reported risks usually outweigh the advantages for
Cite this article as: Lauring JR, Lehman EB, Deimling at 2e16%.3,4 using the method), or category 4
TA, et al. Combined hormonal contraception use in The World Health Organization (unacceptable health risk if the method
reproductive-age women with contraindications to Medical Eligibility Criteria for Contra- is used). Previous studies report that
estrogen use. Am J Obstet Gynecol 2016;215:330.e1-7.
ceptive Use5 and the adapted Centers for 6e11% of current combined oral con-
0002-9378/$36.00 Disease Control and Prevention Medical traceptive users had at least 1 con-
ª 2016 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.ajog.2016.03.047 Eligibility Criteria for contraceptive use6 traindication to combined hormonal
provide evidence-based guidelines for contraception.4,7

330.e1 American Journal of Obstetrics & Gynecology SEPTEMBER 2016


ajog.org GYNECOLOGY Original Research

We described the prevalence of com- The outcome measure is the current use no evidence of disease for 5 years or
bined hormonal contraception use of a combined hormonal contraception, category 4 for current breast cancer), and
among women with medical contraindi- which was defined as combined birth (8) migraine with aura (category 4).
cations to estrogen use in a sample of control pills (containing both estrogen Health conditions were determined
reproductive-age women. Our hypothe- and progestin), the contraceptive patch, by a series of questions asking, “Has a
sis was that women with category 3 or 4 and the vaginal ring. doctor, nurse, or other health profes-
contraindications to estrogen-containing For women using birth control pills, sional ever told you that you had or
contraception would be less likely to use the survey response choice was birth have any of the following?” Smoking
combined hormonal contraception control pills and did not specify com- was assessed by asking, “Do you now
than women without a medical contra- bined pills or progestin-only pills. To smoke cigarettes every day, some days,
indication. We also explored whether make this distinction, pharmacy claims or not at all?” In several cases, our
inappropriate combined hormonal con- data were obtained from Highmark survey tool was unable to distinguish
traception use is related to contraceptive Health and used to determine whether category 3 from category 4 contraindi-
provider characteristics. the most recent pharmacy claim prior to cations. For example, women over the
the woman’s baseline survey was for age of 35 years who smoked every day
Materials and Methods combined or progestin-only oral con- were considered to have a contraindi-
This analysis was performed using the traceptive. All other contraceptives were cation, but we were unable to specify
baseline survey data from the MyNew- considered nonestrogen contraception, whether it was category 3 or 4 because
Options study, an ongoing randomized which included male and female con- the number of cigarettes smoked per
controlled trial to test an online repro- doms, the medroxyprogesterone acetate day was not ascertained.
ductive lifeeplanning intervention for injectable, intrauterine devices, dia- Of note, not all 18 category 3 and 4
assisting privately insured adult women phragm, cervical cap, contraceptive health conditions were ascertained by the
with personalized contraceptive decision foam, jelly, cream or suppository, the survey, so if women in the sample had
making. The sample included 987 female sponge, contraceptive implant, rhythm other category 3 and 4 contraindications
Highmark Health members in Pennsyl- or natural family planning, withdrawal, (severe liver cirrhosis, gallbladder disease,
vania between the ages of 18 and 40 and no method of contraception. liver tumors, peripartum cardiomyopa-
years. Women were eligible for the study thy, organ transplant, thrombogenic
if they were sexually active, not intending Medical contraindications to mutations, and valvular heart disease),
pregnancy in the next 12 months, not combined hormonal contraception they may have been misclassified.
surgically sterilized or with a partner We identified study participants with the
who was surgically sterilized, had following category 3 (theoretical or Contraceptive provider
Internet access and a valid e-mail proven risk usually outweigh the ad- characteristics
address. vantages) and category 4 (unacceptable Contraceptive provider characteristics
Participants then completed a baseline health risk) contraindications to com- were determined by a series of questions
survey that ascertained baseline de- bined hormonal contraception, accord- in which the respondent was asked about
mographics, current method of contra- ing to the Centers for Disease Control “the most recent health care visit where
ception, and their medical comorbidities. and Prevention Summary Chart of US you received any contraceptive or
Randomization and online intervention Medical Eligibility Criteria for Contra- women’s health care services.” The clinic
occurred after the completion of the ceptive Use6: (1) hypertension (category type (private office vs other clinic), spe-
baseline survey. Additional details 3 if adequately controlled or category 4 if cialty (obstetrics and gynecology vs other
regarding the study protocol have been poorly controlled), (2) smokers over the specialties), and provider type (physician
published elsewhere.8 age of 35 years (category 3 if <15 ciga- vs nonphysician provider) in which the
This study was approved by the Penn rettes/day or category 4 if 15 cigarettes/ contraceptive or women’s health care
State Hershey Institutional Review day), (3) a history of venous thrombo- services occurred were recorded.
Board under institutional review board embolism (category 3 if lower risk for
protocol 44583EP with informed con- recurrent venous thromboembolism or Statistical analysis
sent obtained online. category 4 if higher risk for recurrent All variables were summarized with fre-
venous thromboembolism), (4) diabetes quencies and percentages for categorical
Contraceptive method with complications (category 3 if variables or with means, medians, and
The survey measured the current con- microvascular complications or category SDs for continuous variables prior to any
traceptive method by asking women to 4 if vascular disease or diabetes >20 analysis. c2 tests for general association,
indicate the method of contraception years), (5) coronary artery disease with Fisher exact tests substituted as
used within the last month. If more than (category 4), (6) systemic lupus erythe- needed, were used to compare combined
1 choice was selected, participants were matosus with antiphospholipid anti- hormonal contraception use, contra-
then asked, “Which method do you bodies (category 4), (7) breast cancer ceptive health provider characteristics,
consider to be your primary method?” (category 3 if previous breast cancer with and sociodemographics between women

SEPTEMBER 2016 American Journal of Obstetrics & Gynecology 330.e2


Original Research GYNECOLOGY ajog.org

with and without contraindications to


TABLE 1
estrogen.
Characteristics of reproductive-age women with and without
This same approach was then applied
contraindications to CHC use
to only the subgroup of 130 women with
contraindications to combined hor- Women with Women without
monal contraception, making bivariate Total contraindication contraindication
comparisons of health provider charac- Characteristic (n ¼ 987) to CHC (n ¼ 130) to CHC (n ¼ 857) P valuea
teristics and sociodemographics be- Current CHC use .097
tween women with combined hormonal Yes 454 (46.0) 51 (39.2) 403 (47.0)
contraception use and women without
No 533 (54.0) 79 (60.8) 454 (53.0)
combined hormonal contraception use.
All analyses were performed using SAS Nonwhite race .061
version 9.4 (SAS Institute, Cary, NC). Yes 50 (5.1) 11 (8.5) 39 (4.6)
No 931 (94.9) 119 (91.5) 812 (95.4)
Results
Education .803
Characteristics of the study sample (n ¼
987) are shown in Table 1. Of the total High school graduate or less 70 (7.1) 9 (7.0) 61 (7.1)
sample, 13.2% of the women (n ¼ 130) Some college 318 (32.4) 45 (34.9) 273 (32.0)
had a contraindication to combined College graduate 595 (60.5) 75 (58.1) 520 (60.9)
hormonal contraception. The most
Income .691
common contraindication was migraine
with aura (n ¼ 105, 80.7%). Of the <$25,000 133 (13.9) 14 (10.9) 119 (14.4)
remaining 25 women with a contrain- $25,000e$49,999 243 (25.4) 32 (25.0) 211 (25.5)
dication, conditions included age 35 $50,000e$74,999 233 (24.4) 31 (24.2) 202 (24.4)
years smokers (n ¼ 9, 6.9%), hyperten-
$75,000 347 (36.3) 51 (39.8) 296 (35.8)
sion (n ¼ 14, 10.8%), a history of venous
thromboembolism (n ¼ 5, 3.9 %), and Body mass index, kg/m 2
< .001b
diabetes with complications (n ¼ 2, Underweight (<18.5) 27 (2.8) 5 (3.9) 22 (2.6)
1.5%). Five women had 2 medical con- Normal (18.5 to <25) 542 (55.1) 50 (38.8) 492 (57.6)
ditions that were contraindications to
Overweight (25 to <30) 220 (22.4) 36 (27.9) 184 (21.6)
combined hormonal contraception,
which included 2 patients with migraine Obese (30) 194 (19.7) 38 (29.5) 156 (18.3)
with aura and hypertension, 2 smokers Contraception managed by .709
with hypertension, and 1 smoker with a obstetrician-gynecologist
history of venous thromboembolism. Yes 672 (82.0) 92 (80.7) 580 (82.2)
Results of the bivariate analysis
No 148 (18.0) 22 (19.3) 126 (17.8)
comparing women with and without
contraindications to combined hor- Contraception managed by .852
physician
monal contraception are summarized in
Table 1. There were no statistically sig- Yes 566 (71.0) 78 (70.3) 488 (71.1)
nificant differences between women with No 231 (29.0) 33 (29.7) 198 (28.9)
and without contraindication to com- Contraception managed by .278
bined hormonal contraception with re- private doctor’s office
gard to race, education, income, or Yes 826 (87.5) 114 (90.5) 712 (87.0)
contraceptive provider characteristics.
Women with a contraindication to No 118 (12.5) 12 (9.5) 106 (13.0)
combined hormonal contraception were CHC, combined hormonal contraception.

more likely to be overweight and obese


a
P value from c2 test for general association, exact test used as needed; b statistically significant.
Lauring et al. Combined hormonal contraception in women with contraindications Am J Obstet Gynecol 2016.
compared with women without contra-
indications to combined hormonal
contraception use (27.9% vs 21.6% and
29.5% vs 18.3% respectively, P < .001).
the mean age of the women with con- years. Only 12 women (1.2%) indicated contraception, 39.2% (n ¼ 51) were
traindications was 28.85  6.23 years, Hispanic ethnicity. using combined hormonal contracep-
and the mean age of the women without Among the 130 women with a tion. This was not statistically different
contraindications was 26.88  5.92 contraindication to combined hormonal from women without a contraindication

330.e3 American Journal of Obstetrics & Gynecology SEPTEMBER 2016


ajog.org GYNECOLOGY Original Research

(47.0%, P ¼ .1). The bivariate analysis


TABLE 2
describing combined hormonal contra-
Characteristics associated with CHC use among women with known
ception use among the subset of women
contraindications to CHC use
with contraindications to combined
Total CHC users Non-CHC users hormonal contraception (n ¼ 130) are
Characteristic (n ¼ 130) (n ¼ 51) (n ¼ 79) P valuea summarized in Table 2.
Medical comorbidity Combined hormonal contraception
Migraine with aura 105 (80.7) 43 (84.3) 62 (79.5) .551
use did not differ by education level,
income, or weight category. There were
Age 35 y smokers 9 (6.9) 2 (3.9) 7 (8.9) .321 also no differences in contraceptive
Hypertension 14 (10.8) 3 (5.9) 11 (13.9) .149 provider specialty, provider type, or
Other b
7 (5.4) 3 (5.9) 4 (3.1) 1.000 clinic type. Combined hormonal con-
traception nonusers were more likely to
Age, y .422
be nonwhite than combined hormonal
35 33 (25.4) 11 (21.6) 22 (27.9) contraception users (12.7% vs 2.0%
<35 97 (74.6) 40 (80.4) 57 (72.6) P ¼ .049). The mean age of combined
Nonwhite race .049c hormonal contraception users was 27.51
 6.02 years and nonusers, 29.71  6.25
Yes 11 (8.5) 1 (2.0) 10 (12.7)
years. A total of 21.6% of users (n ¼ 11)
No 119 (91.5) 50 (98.0) 69 (87.3) and 27.9% of nonusers (n ¼ 22) were
Education .155 35 years (P ¼ .422).
High school graduate or less 9 (7.0) 1 (2.0) 8 (10.3) The largest group of women with
contraindications to combined hor-
Some college 45 (34.9) 17 (33.3) 28 (35.9)
monal contraception were those with
College graduate 75 (58.1) 33 (64.7) 42 (53.9) migraine with aura; therefore, we per-
Income .470 formed a post hoc analysis of just women
<$25,000 14 (10.9) 6 (11.8) 8 (10.4) with migraines to determine whether
women with and without aura had dif-
$25,000e$49,999 32 (25.0) 9 (17.7) 23 (29.9)
ferences in contraceptive use. Of the total
$50,000e$74,999 31 (24.2) 13 (25.5) 18 (23.4) sample, 23.4% (n ¼ 231) reported that
$75,000 51 (39.8) 23 (45.1) 28 (36.4) they suffered from migraine headaches;
Body mass index, kg/m 2
.394 among whom, 45.5% (n ¼ 105) reported
experiencing aura, which was ascer-
Underweight (<18.5) 5 (3.9) 3 (5.9) 2 (2.6)
tained by the question, “Do you get
Normal (18.5 to <25) 50 (38.8) 23 (45.1) 27 (34.6) migraine auras? Symptoms of migraine
Overweight (25 to <30) 36 (27.9) 11 (21.6) 25 (32.1) aura can include changes in vision (blind
Obese (30) 38 (29.5) 14 (27.5) 24 (30.8) spots, seeing flashing lights, or zigzag
lines), feeling prickling skin, having dif-
Contraception managed by .723
obstetrician-gynecologist ficulty speaking, or seeing things that are
not there (hallucinations).” There was no
Yes 92 (80.7) 38 (79.2) 54 (81.8) statistically significant difference in
No 22 (19.3) 10 (20.8) 12 (18.2) combined hormonal contraception use
Contraception managed by .891 between women with migraine with
physician aura and those without (40.9% vs 46.8%,
Yes 78 (70.3) 32 (69.6) 46 (70.8) P ¼ .371).
No 33 (29.7) 14 (30.4) 19 (29.2)
Comment
Contraception managed by .358 Among this study sample of privately
private doctor’s office
insured reproductive-age women, there
Yes 114 (90.5) 48 (94.1) 66 (88.0) was a high rate (39.2%) of combined
No 12 (9.5) 3 (5.9) 9 (12.0) hormonal contraception use among
CHC, combined hormonal contraception. women with a medical contraindication
a
P value from c2 test for general association, exact test used as needed; b Other includes history of venous thromboembolism to estrogen use. In fact, they were statis-
and diabetes with complications. These groups were combined because of small numbers; c statistically signifcant. tically no less likely to be using combined
Lauring et al. Combined hormonal contraception in women with contraindications Am J Obstet Gynecol 2016. hormonal contraception than women
without a medical contraindication to

SEPTEMBER 2016 American Journal of Obstetrics & Gynecology 330.e4


Original Research GYNECOLOGY ajog.org

estrogen use. Almost half of women with (long-acting reversible contraceptives). Studies suggest there is an increased
migraine with aura, an unacceptable Long-acting reversible contraceptives, risk among migraine patients who are
health risk, were using combined hor- which include intrauterine devices and using combined hormonal contracep-
monal contraception in our sample. the contraceptive implant, are the most tion,14,17,18,22,23 although the risk of
Previous literature has shown lower effective reversible contraceptive ischemic stroke may be lower with low-
rates of combined hormonal contracep- methods currently available. dose estrogen preparations.20,22
tion use among women with contrain- Reducing unintended pregnancy by One limitation of our study is we were
dications compared with those without, increasing access to contraception has not able to distinguish whether some
although the association was no longer led to interest in over-the-counter oral women had category 3 (theoretical or
significant when controlling for socio- contraception. Whereas opponents have proven risk usually outweigh the ad-
demographic characteristics.3 Among argued that requiring a prescription al- vantages) or category 4 (unacceptable
the combined hormonal contraception lows providers to assess women for health risk) contraindications to com-
users, 11.23% had a contraindication to contraindications to combined hor- bined hormonal contraception. For
estrogen, similar to previously published monal contraception, our study results example, we ascertained whether
data.4,7 There were no differences in suggest that the current process is not women had hypertension but did not
contraceptive provider or clinic charac- effectively helping women obtain the have information on how well it was
teristic between those using combined safest methods for their individual controlled: adequately controlled hy-
hormonal contraception and those who characteristics. Previous studies have pertension is category 3 and poorly
were not. shown women are able to accurately self- controlled hypertension is category 4.
The concerns about combined hor- screen for contraindications to estrogen Similarly, we included women over
monal contraception use when contra- with a medical checklist.11 In a recent age 35 years who reported smoking every
indications are present center on survey of US women at risk for preg- day but do not know whether they
cardiovascular risk. Although combined nancy, more than 60% of the re- smoked <15 cigarettes/day (category 3)
hormonal contraception has consistently spondents were in favor of over-the- or 15 cigarettes/day (category 4).
been associated with an increased rela- counter access to over-the-counter oral Additionally, patients who reported
tive risk of venous thromboembolism,9 contraception, and almost one third of smoking some days may influence pre-
the overall absolute risk remains low, women not currently using contracep- scribing patterns, which was not
especially compared with the risk asso- tion said they were likely to start using addressed in our study.
ciated with pregnancy. A recent over-the-counter oral contraception if The high use of combined hormonal
Cochrane Review suggested there is no available over the counter.12 contraception in women with contrain-
increased risk of arterial thrombosis The largest contraindication category dications could be a result of patient and
including myocardial infarction or in our study sample was migraine with provider acceptance of the increased
ischemic stroke, in average-risk oral aura, which is classified as a category 4, associated risk with combined hormonal
contraceptive users with estrogen for- or unacceptable health risk. In our study, contraception in favor of the contra-
mulations <50 mg.10 However, for almost half of the women with migraines ceptive and noncontraceptive benefits
women with certain medical comorbid- reported having migraines with aura, associated with combined hormonal
ities, estrogen-containing contraception, and almost half of the women with contraception in women with category 3
or combined hormonal contraception, migraine with aura were using combined contraindications. However, less than
increases their risk of these cardiovas- hormonal contraception. Research has 20% of patients could potentially have
cular complications2 and should be suggested that migraine headaches are had a category 3 contraindication;
avoided. associated with an increased risk of therefore, most women with contrain-
Our study was designed using the ischemic stroke,13-15 with an increased dications in our study were using com-
Centers for Disease Control and Pre- risk in women with migraine with aura bined hormonal contraception despite
vention medical eligibility criteria, but when compared with those with unacceptable health risk.
there are women with increased cardio- migraine without aura.16-18 Another possible explanation for the
vascular risk because of multiple risk The association between ischemic similar rates of combined hormonal
factors such as obese women who smoke stroke and migraine also appears stron- contraception use could be a lack of
or have migraines, for which this ger in younger women, particularly knowledge of contraindications to
guideline is less clear. Although not those younger than 34 years to 45 combined hormonal contraception by
addressed in our study, this group would years.15,16 Use of hormonal contracep- both the prescriber and the patient.
be of interest in future research. tion, particularly containing estrogen, is Previous research has demonstrated
Processes need to be improved to independently associated with an more than 30% of surveyed obstetrician-
ensure that women with medical con- increased risk of ischemic stroke.19,20 gynecologists and family physicians dis-
traindications are being offered the This risk increases with age, smoking, agreed with a statement that “migraine
safest and most effective noneestrogen- and other medical comorbidities that with aura should not be prescribed”
containing methods, including LARCs increase the risk of ischemic stroke.21 combined hormonal contraception.24

330.e5 American Journal of Obstetrics & Gynecology SEPTEMBER 2016


ajog.org GYNECOLOGY Original Research

The Centers for Disease Control and bias is minimized with anonymous seeking combined hormonal contraception. Am
Prevention and World Health Organi- electronic surveys, this could still influ- J Obstet Gynecol 2014;210:210.e1-5.
5. World Health Organization. Reproductive
zation rate this a category 4, and this was ence patient reporting. Health and Research. Medical eligibility criteria
the largest group in our study at greater Many factors contribute to the deci- for contraceptive use, 4th ed. Geneva: Depart-
than 80%. This highlights the need for sion on contraceptive method. The de- ment of Reproductive Health and Research,
adequate provider education on appro- cision may be based on safety, efficacy, World Health Organization; 2010.
priate patient selection for the varying perceived pregnancy risk, desire for 6. Centers for Disease Control and Preven-
tion. US medical eligibility criteria for con-
contraceptive methods. future pregnancy, and method.28-30 The traceptive use, 2010: adapted from the World
The choice to use combined hor- decision also depends on access, avail- Health Organization Medical Eligbibility
monal contraception when contra- ability, and cost of a particular method.31 Criteria for Contraceptive Use. 4th ed.
indicated could also be related to cost The majority of women in our study MMWR Morb Mortal Wkly Rep 2010;59
considerations. Although our study was were college graduates, more than one (RRO4):1-6.
7. Grossman D, White K, Hopkins K, Amastae J,
conducted in a sample of privately third reported an income $75,000, Shedlin M, Potter JE. Contraindications to
insured women after the Affordable Care more than half were normal weight or combined oral contraceptives among over-the-
Act’s contraceptive coverage mandate, underweight, and there were very few counter compared with prescription users.
we have previously reported that Hispanic women in the study. The de- Obstet Gynecol 2011;117:558-65.
awareness of contraceptive coverage in cision to use combined hormonal 8. Chuang CH, Velott DL, Weisman CS, et al.
Reducing unintended pregnancies through
this sample is low.25 contraception for these women may not web-based reproductive life planning and con-
Another possible explanation for our be generalizable to all populations. traceptive action planning among privately
negative finding is a result of type II er- However, expansion of contraceptive insured women: study protocol for the
ror. A post hoc power analysis results in benefits through the Affordable Care Act MyNewOptions randomized, controlled trial.
only 38% power for a 2-sided c2 test can provide the opportunity for women Womens Health Issues 2015;25:641-8.
9. Food and Drug Administration. Combined
using a significance level of P ¼ .05. with contraindications to estrogen to hormonal contraceptives (CHC) and the risk of
However, our study still highlights a choose a safer, more effective method cardiovascular disease endpoints. Silver Spring
large number of women with contrain- without cost concerns. (MD): Food and Drug Administration; 2011.
dications to estrogen using combined In our study, inappropriate combined 10. Roach RE, Helmerhorst FM, Lijfering WM,
hormonal contraception who could hormonal contraception use was not Stijnen T, Algra A, Dekkers OM. Combined oral
contraceptives: the risk of myocardial infarction
potentially benefit from safer, more related to contraceptive provider char- and ischemic stroke. Cochrane Database Syst
effective methods of contraception. acteristics, suggesting contraceptive Rev 2015;8:Cd011054.
A limitation of our study is that we providers of all types and specialties can 11. Grossman D, Fernandez L, Hopkins K,
relied on self-report of medical comor- play a greater role in identifying contra- Amastae J, Garcia SG, Potter JE. Accuracy of
bidities and did not verify through ceptive contraindications and offering self-screening for contraindications to combined
oral contraceptive use. Obstet Gynecol
medical records. Previous studies, how- safer alternatives. n 2008;112:572-8.
ever, have shown strong concordance 12. Grossman D, Grindlay K, Li R, Potter JE,
between physician screening and patient Acknowledgments Trussell J, Blanchard K. Interest in over-the-
reporting of medical comorbidities for Study data were collected and managed using counter access to oral contraceptives among
contraindications to combined hor- REDCap electronic data capture tools hosted at women in the United States. Contraception
the Penn State Milton S. Hershey Medical Center 2013;88:544-52.
monal contraception, 90% or higher for 13. Nightingale AL, Farmer RD. Ischemic stroke
and College of Medicine. This study had the
many of the conditions we studied.26 study Identifier of NCT02100124 (ClinicalTrials. in young women: a nested case-control study
In our study, there were higher gov). We thank Highmark Health for their assis- using the UK General Practice Research Data-
numbers of migraine with aura than in tance with participant recruitment. base. Stroke 2004;35:1574-8.
previous studies. This could also be a 14. Lidegaard O. Oral contraceptives, preg-
nancy and the risk of cerebral thromboembo-
result of self-report of medical condi- References lism: the influence of diabetes, hypertension,
tions or selection bias of patients who 1. Daniels K, Mosher WD. Contraceptive migraine and previous thrombotic disease. Br J
chose to participate in our study. Previ- methods women have ever used: United States, Obstet Gynaecol 1995;102:153-9.
ous research has suggested that patient 1982e2010. Natl Health Stat Report 2013: 15. Carolei A, Marini C, De Matteis G. History of
report of migraine also has a high degree, 1-15. migraine and risk of cerebral ischaemia in young
2. American College of Obstetricians and Gy- adults. The Italian National Research Council
>87%, of agreement with International Study Group on Stroke in the Young. Lancet
necologists. Use of hormonal contraception in
Classification of Headache Disorderse women with coexisting medical conditions. 1996;347:1503-6.
based migraine classification,27 but there ACOG Practice bulletin no. 73. Obstet Gynecol 16. Schürks M, Rist PM, Bigal ME, Buring JE,
are few data regarding the agreement of 2006;107:1453-72. Lipton RB, Kurth T. Migraine and cardiovascular
self-reported aura. Future research on 3. Shortridge E, Miller K. Contraindications to disease: systematic review and meta-analysis.
oral contraceptive use among women in the BMJ 2009;339:b3914.
this topic should include access to 17. Tzourio C, Tehindrazanarivelo A, Iglésias S,
United States, 1999e2001. Contraception
medical records to confirm the diag- 2007;75:355-60. et al. Case-control study of migraine and risk of
nosis. Our study was survey based, and 4. Xu H, Eisenberg DL, Madden T, Secura GM, ischaemic stroke in young women. BMJ
although the risk of social desirability Peipert JF. Medical contraindications in women 1995;310:830-3.

SEPTEMBER 2016 American Journal of Obstetrics & Gynecology 330.e6


Original Research GYNECOLOGY ajog.org

18. Etminan M, Takkouche B, Isorna FC, providers’ assessment of hormonal contracep- Gynecology (Dr Legro), and Division of General Internal
Samii A. Risk of ischaemic stroke in people tive risk factors. Contraception 2006;73:501-6. Medicine, Department of Medicine (Dr Chuang), Penn
with migraine: systematic review and meta- 27. Schürks M, Buring JE, Kurth T. Agreement State Milton S. Hershey Medical Center, Hershey, PA.
analysis of observational studies. BMJ 2005; of self-reported migraine with ICHD-II criteria in Received Feb. 3, 2016; revised March 25, 2016;
330:63. the Women’s Health Study. Cephalalgia accepted March 28, 2016.
19. Lidegaard O. Oral contraception and risk of 2009;29:1086-90. The views expressed herein are those of the authors
a cerebral thromboembolic attack: results of a 28. Cepuliene R, Sveikatiene R, Gutauskas K, and do not necessarily represent the official views of
case-control study. BMJ 1993;306:956-63. Vanagiene V. Factors influencing women’s pref- National Institutes of Health or the National Center for
20. Gillum LA, Mamidipudi SK, Johnston SC. erence to select a combined hormonal contra- Advancing Translational Sciences or the Patient-Centered
Ischemic stroke risk with oral contraceptives: A ceptive method: a cross-sectional survey in Outcomes Research Institute, its Board of Governors, or
meta-analysis. JAMA 2000;284:72-8. Lithuania. Medicina (Kaunas) 2012;48:424-30. Methodology Committee. The findings and conclusions
21. Bushnell C, McCullough L. Stroke preven- 29. Egarter C, Frey Tirri B, Bitzer J, et al. presented are solely those of the authors and do not
tion in women: synopsis of the 2014 American Women’s perceptions and reasons for choosing represent the views of Highmark Health.
Heart Association/American Stroke Association the pill, patch, or ring in the CHOICE study: a All statements in this report, including its findings
guideline. Ann Intern Med 2014;160:853-7. cross-sectional survey of contraceptive method and conclusions, are solely those of the authors and
22. Schwartz SM, Petitti DB, Siscovick DS, et al. selection after counseling. BMC Womens Health do not necessarily represent the views of Highmark
Stroke and use of low-dose oral contraceptives 2013;13:9. Health.
in young women: a pooled analysis of two US 30. Frost JJ, Darroch JE. Factors associated The funding source had no role in the study design; in
studies. Stroke 1998;29:2277-84. with contraceptive choice and inconsistent the collection, analysis, and interpretation of the data; in
23. Chang CL, Donaghy M, Poulter N. Migraine method use, United States, 2004. Perpect Sec the writing of the report; and in the decision to submit the
and stroke in young women: case-control study. Reprod Health 2008;40:94-104. article for publication.
The World Health Organisation Collaborative 31. Weisman CS, Lehman EB, Legro RS, REDCap is supported by the Penn State Clinical and
Study of Cardiovascular Disease and Steroid Velott DL, Chuang CH. How do pregnancy in- Translational Science Institute, Pennsylvania State Uni-
Hormone Contraception. BMJ 1999;318:13-8. tentions affect contraceptive choices when cost versity Clinical and Translational Science Institute, Na-
24. Dehlendorf C, Levy K, Ruskin R, Steinauer J. is not a factor? A study of privately insured tional Institutes of Health/National Center for Advancing
Health care providers’ knowledge about con- women. Contraception 2015;92:501-7. Translational Sciences grant UL1 TR000127.
traceptive evidence: a barrier to quality family This study was supported through a Patient-Centered
planning care? Contraception 2010;81:292-8. Outcomes Research Institute program award (CD-1304-
25. Chuang CH, Mitchell JL, Velott DL, et al. Author and article information 6117).
Women’s awareness of their contraceptive From the Division of Maternal Fetal Medicine, Department R.S.L. is a consultant for Bayer, Takeda Pharmaceu-
benefits under the Patient Protection and of Obstetrics and Gynecology (Dr Lauring), Department tical Company, and Lupin Pharmaceuticals and has other
Affordable Care Act. Am J Public Health of Public Health Sciences (Mr Lehman), Division of research funded by Astra-Zeneca, Ferring Pharmaceuti-
2015;105:S713-5. Minimally Invasive Gynecologic Surgery, Department cals. The other authors report no conflict of interest.
26. Shotorbani S, Miller L, Blough DK, of Obstetrics and Gynecology (Dr Deimling), Division of Corresponding author: Julianne R. Lauring MD.
Gardner J. Agreement between women’s and Reproductive Endocrinology, Department of Obstetrics and jlauring@hmc.psu.edu

330.e7 American Journal of Obstetrics & Gynecology SEPTEMBER 2016

Você também pode gostar